These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31324092)

  • 41. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
    Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
    Olayanju O; Esmail A; Limberis J; Dheda K
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delamanid Resistance: Update and Clinical Management.
    Nguyen TVA; Anthony RM; Cao TTH; Bañuls AL; Nguyen VAT; Vu DH; Nguyen NV; Alffenaar JC
    Clin Infect Dis; 2020 Dec; 71(12):3252-3259. PubMed ID: 32521000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
    Kwon YS; Jeon D; Kang H; Yim JJ; Shim TS
    Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33093123
    [No Abstract]   [Full Text] [Related]  

  • 47. An Experience with Delamanid in an XDR TB Case - Case Report.
    Mohan N; Kaur M; Singhal L; Saini V; Chander J
    Infect Disord Drug Targets; 2021; 21(4):637-639. PubMed ID: 32691718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Chang KC; Leung EC; Law WS; Leung WM; Tai LB; Lee SN; Lam FM; Chau CH; Mok TY; Yew WW; Leung CC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29650556
    [No Abstract]   [Full Text] [Related]  

  • 49. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of
    Negi A; Perveen S; Gupta R; Singh PP; Sharma R
    J Med Chem; 2024 Feb; 67(4):2264-2286. PubMed ID: 38351709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis.
    Putra ON; Yulistiani Y; Soedarsono S
    Int J Mycobacteriol; 2022; 11(4):349-355. PubMed ID: 36510917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
    Mallikaarjun S; Chapagain ML; Sasaki T; Hariguchi N; Deshpande D; Srivastava S; Berg A; Hirota K; Inoue Y; Matsumoto M; Hafkin J; Geiter L; Wang X; Gumbo T; Liu Y
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients.
    Acquah R; Mohr-Holland E; Daniels J; Furin J; Loveday M; Mudaly V; Reuter A
    Pediatr Infect Dis J; 2021 May; 40(5):e191-e192. PubMed ID: 33847295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature.
    Esposito S; Bosis S; Tadolini M; Bianchini S; Migliori GB; Principi N
    Medicine (Baltimore); 2016 Nov; 95(46):e5347. PubMed ID: 27861363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.
    Mukherjee A; Lodha R; Kabra SK
    Expert Opin Pharmacother; 2017 Oct; 18(15):1595-1606. PubMed ID: 28847228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q; Ming WK; Yip WY; You JHS
    Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
    Yoon HY; Jo KW; Nam GB; Shim TS
    Int J Tuberc Lung Dis; 2017 Sep; 21(9):996-1001. PubMed ID: 28826448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS.
    Pstragowski M; Zbrzezna M; Bujalska-Zadrozny M
    Acta Pol Pharm; 2017 Jan; 74(1):3-11. PubMed ID: 29474756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. India plans to expand access to new tuberculosis drug.
    Sharma DC
    Lancet; 2017 Feb; 389(10070):685. PubMed ID: 28229866
    [No Abstract]   [Full Text] [Related]  

  • 60. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
    Lessem E; Cox H; Daniels C; Furin J; McKenna L; Mitnick CD; Mosidi T; Reed C; Seaworth B; Stillo J; Tisile P; von Delft D
    Int J Infect Dis; 2015 Mar; 32():56-60. PubMed ID: 25809757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.